Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant

W M Drake1, D M Berney2, K Kovacs3 and J P Monson1
Departments of 1Endocrinology and 2Histopathology, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, UK and 3St Michael’s Hospital, Department of Laboratory Medicine and Pathobiology, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada

(Correspondence should be addressed to W M Drake; Email: w.m.drake@qmul.ac.uk)

Abstract
We report our findings on markers of cell proliferation (Ki-67 labelling index and topoisomerase-α expression) in a somatotroph pituitary tumour before and after exposure to pegvisomant, a GH receptor antagonist developed for the treatment of acromegaly. Specimens from two separate pituitary operations, separated by a period of 17 years that included 4 years of pegvisomant treatment, were stained for markers of cellular proliferation. Ki-67 labelling index and topoisomerase-α expression were both markedly greater (1–3% compared with 0–0.5% and 15–80% compared with 2–10% respectively) in the pegvisomant-exposed tumour compared with the earlier specimen. Clearly, caution must be exercised when interpreting findings from a single case, particularly one sufficiently refractory to conventional therapies to require treatment with pegvisomant. However, our data reinforce the requirement for careful radiological surveillance of the pituitary in the context of a drug that does not target the tumour responsible and where serum GH cannot serve as a marker of disease activity or tumour size.

European Journal of Endocrinology 153 203–205

Introduction
Pegvisomant is a pegylated analogue of human growth hormone (GH) licensed for use in the treatment of acromegaly (1–3). Unlike other medical treatments, pegvisomant does not target the pituitary tumour responsible for excess GH secretion. Serum GH concentrations increase during pegvisomant therapy, probably as a result of increased pituitary secretion rather than decreased circulatory clearance (4), leading to speculation that pegvisomant therapy may be associated with a Nelson’s syndrome-like effect (5), in which interruption of GH-mediated negative feedback leads to subsequent tumour expansion. Currently, there is no evidence that pegvisomant therapy causes an increase in pituitary tumour volume (3), but it should be remembered that pituitary tumours are often slow growing, and that Nelson’s syndrome may develop after many years (4). Pituitary tumour immunohistochemistry before and after treatment with pegvisomant may provide early indication of the potential for this drug to provoke tumour enlargement. We report our findings on markers of cell proliferation in a somatotroph pituitary tumour before and after pegvisomant therapy.

Case report
Acromegaly was diagnosed, in 1976, in a 16-year-old girl with secondary amenorrhea. The mean serum GH concentration was ~400 mU/L decreasing to ~150 mU/L with bromocriptine 40 mg daily (‘safe’ GH concentrations for treated acromegaly are <5 mU/L). External pituitary irradiation was followed, shortly after, by probable pituitary apoplexy. In 1977, the patient underwent trans-sphenoidal surgery with removal of GH-staining adenoma. Between 1978 and 1986 there was massive expansion of the tumour through the right cavernous sinus into the infratemporal fossa, with an increase in serum GH from 42 to >1000 mU/L and intractable trigeminal pain, requiring craniotomy and transfrontal resection of intra-cavernous-sinus tumour. The pain improved and serum GH concentrations decreased to ~350 mU/L. In 1988, the patient received stereotactic radiotherapy to an orbital extension of tumour, but the infratemporal portion could not be safely targeted. GH concentrations decreased to ~200 mU/L. In 1991, a nadir GH of 70 mU/L was achieved with subcutaneous octreotide 2500 μg daily by continuous infusion. Treatment with cabergoline caused adverse psychological symptoms. Two cycles of chemotherapy (lomustine and 5-fluorouracil) were unsuccessful.
In 1997, the patient enrolled in a randomized trial, and pegvisomant 30 mg weekly was commenced, with subsequent increments to 40 mg daily during an open-label, daily-dosing phase (3), with good symptomatic and biochemical results. Treatment was suspended between 2000 and 2002 because of a shortage of the drug; during this period the patient received 30 mg monthly of depot octreotide (Novartis), with symptomatic and biochemical deterioration (increased fatigue and sweating in association with a serum insulin-like growth factor (IGF)-I concentrations consistently greater than 1000 ng/ml). After recommencement of pegvisomant in 2002, inadequate biochemical control was achieved with 40 mg daily and the dose was increased to 60 mg. In 2003, the patient underwent transmaxillary removal of most of the infra-temporal-fossa tumour extension. Symptomatic and biochemical improvement were immediate (reduced fatigue and sweating, normal serum IGF-I concentration). Progressive decrements in the dose of pegvisomant were made, indicating a reduced GH burden, but the patient developed a staphylococcal septicaemia and died. No source was identified at postmortem examination.

Materials and methods

Specimens from 1986 and 2003 were fixed in formalin, paraffin embedded, cut and stained for immunohistochemistry using the streptavidin–biotin–peroxidase complex method. No material was available for electron microscopic study.

Results

By histology, both tumours (Fig. 1) were atypical, partly acidophilic, partly chromophobic somatotroph adenomas showing marked cellular and nuclear pleomorphism. The tumour cells were immunoreactive for GH, but immunonegative for the other adenohypophysial hormones (prolactin, adrenocorticotrophic hormone, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone and alpha subunit). Minor differences included slightly more pronounced fibrosis, slightly greater expression of vascular endothelial growth factor (VEGF), slightly more intense GH immunoreactivity and decreased number of keratin-positive intracytoplasmic fibrous bodies in the post-pegvisomant tumour as compared with the tumour not exposed to pegvisomant. No differences were noted in the rate of mitosis, vascularity, cellular and nuclear pleomorphism, E-cadherin expression, S-100 protein and glial fibrillary acidic protein (GFAP) immunoreactivity. Neurofilament antigen was negative in the tumour cells. Immunostainings for p53, cyclo-oxygenase-2, p27 and proliferating cell nuclear antigen yielded inconclusive results.

Two conspicuous differences between the specimens were apparent. Firstly, the Ki-67 labelling index (a marker of rate of cell proliferation) was markedly greater (1–3%) in the pegvisomant-exposed tumour compared with the earlier specimen (0–0.5%). Secondly, expression of topoisomerase 2α (another marker of cell proliferation) was greater in the second specimen (15–80% compared with 2–10%). This suggests that more cells proliferated in the tumour removed after pegvisomant treatment than in the
1986 specimen. Marginally greater fibrosis, VEGF expression and GH immunoreactivity and slightly fewer keratin-positive intracytoplasmic fibrous bodies were noted in the tumour exposed to pegvisomant.

**Discussion**

To our knowledge, this is the first report of somatotroph pituitary tumour immunohistochemistry before and after exposure to pegvisomant. Although, to date, there is no evidence of a change in mean tumour volume in patients treated with pegvisomant (3), our findings raise the possibility that the drug may cause enhanced tumour cell proliferation and, by implication, subsequent accelerated tumour growth. Clearly, caution is needed when interpreting findings from a single case. It is possible that the tissue examined was not representative of the entire tumour. It must also be emphasized that 11 years elapsed between the 1986 craniotomy and the commencement of pegvisomant treatment in 1997, such that the changes reported above may have occurred during this period, independent of pegvisomant. Against this argument is the observation that the earlier specimen was obtained at a time of maximum tumour growth rate (serum GH increased from 42 to >1000 mU/l and the infratemporal fossa was invaded after trans-sphenoidal surgery in 1978). After the 1986 craniotomy and subsequent stereotactic radiotherapy, tumour volume was relatively static, with only a 1 ml (6%) increase after the commencement of pegvisomant.

It will take several years of follow-up to establish whether pegvisomant therapy is associated with accelerated tumour growth. Despite the limitations of our study, we feel it important to report the finding that the Ki-67 labelling index and expression of topoisomerase 2α, both markers of cellular proliferation, increased over a period of time, during which our patient received pegvisomant. We encourage similar studies in other acromegalic patients exposed to pegvisomant. Careful radiological surveillance is clearly mandatory in the context of a drug that does not target the tumour responsible and where serum GH cannot serve as a marker of disease activity or tumour size.

**References**


Received 8 April 2005
Accepted 10 May 2005